Monograph
N05AA01 - Chlorpromazine |
Not porphyrinogenic |
NP |
Rationale
Neuroleptic, frequently used in acute porphyria without any adverse effects. No indications of CYP-inducing effects. Several references state non-porphyrinogenicity. Since long recommended for use during acute porphyric crises.
Chemical description
High-dose neuroleptic phenothiazine with aliphatic side chain. Broad therapeutic spectrum including antipsychotic, sedative and antiemetic effects. Metabolized by CYP 2D6. MFM James, RJ Hift. Porphyrias. Br J Anaesth 2000; 85, 143-53: use (phenothiazines). EPI-list: safe Australian list: safe Merck: safe South African list: use French list: use Kalman, Bonkovsky: safe Moore MR, Hift RJ: Drugs in the acute porphyrias. Cell Mol Biol 43:89, 1997: safe
IPNet drug reports
Uneventful use reported in 14 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway
Poland
Finland
Serbia© NAPOS 2024